United Therapeutics (UTHR) Misses Q4 EPS by $2.05, Misses on Revenue
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $544.33 +1.12%
EPS Growth %: +12.6%
Financial Fact:
Interest expense: -500K
Today's EPS Names:
CRWS, MEI, PODC, More
EPS Growth %: +12.6%
Financial Fact:
Interest expense: -500K
Today's EPS Names:
CRWS, MEI, PODC, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $2.67, $2.05 worse than the analyst estimate of $4.72. Revenue for the quarter came in at $491.5 million versus the consensus estimate of $519.21 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- MSCI acquires First Street for $120M to expand climate risk data
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
